trial

Response to Clozapine in Treatment Resistant Schizophrenia: A Longitudinal Magnetic Resonance Spectroscopy Study

NCTId NCT02714894
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase — · Unknown
Enrollment 108 (estimated)
Sponsored by Centre for Addiction and Mental Health
Primary completion 2022-07-30
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Unknown
Enrollment
108 (estimated)
Study type
Observational
Allocation
—
Model
—
Masking
—
Start
2016-04
Primary completion
2022-07-30
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
Clozapine

Sponsors

Centre for Addiction and Mental HealthLead Sponsor
Canadian Institutes of Health Research (CIHR)Collaborator

Investigators

1
Ariel Graff, MD, PhDPrincipal Investigator

Sites

1 total
Toronto, Canada

Facts & assertions

4 sourced
Enrollment
108
Phase
NA
Primary Completion Date
2022-07-30
Status
UNKNOWN
relationships
The graph out of here
drug
Clozapine
drug
lead_sponsor
Centre for Addiction and Mental Health
company
collaborator
Canadian Institutes of Health Research (CIHR)
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Ariel Graff, MD, PhD
person